Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients

Cytoreductive surgery (CRS) with hyperthermic perioperative chemotherapy (HIPEC) has become a treatment option for selected patients with peritoneal metastases (PMs) from gastrointestinal malignancies. The purpose of this study is to evaluate our most recent data regarding pulmonary complications (r...

Full description

Saved in:
Bibliographic Details
Main Authors: Vinicius Preti, David Chang, Paul H. Sugarbaker
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2012/635314
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849692432869883904
author Vinicius Preti
David Chang
Paul H. Sugarbaker
author_facet Vinicius Preti
David Chang
Paul H. Sugarbaker
author_sort Vinicius Preti
collection DOAJ
description Cytoreductive surgery (CRS) with hyperthermic perioperative chemotherapy (HIPEC) has become a treatment option for selected patients with peritoneal metastases (PMs) from gastrointestinal malignancies. The purpose of this study is to evaluate our most recent data regarding pulmonary complications (respiratory distress, pleural effusion, and pneumonia) and attempt to identify risk factors associated with this management plan. This study includes the most recent 4-year experience with appendiceal and colorectal carcinomatosis patients treated in a uniform manner between January 1, 2006 and December 31, 2009. A prospective morbidity and mortality database was maintained and pulmonary adverse events were analyzed with special attention to subphrenic peritonectomy. There were 147 consecutive patients with a mean age of 49.9 years. Fourteen patients (10%) presented grades I–IV pulmonary complications for a total of 26 events. The peritonectomy of right upper quadrant was performed in 74% and right plus left in 49% of the patients. Statistically, there were no more pulmonary complications among patients submitted to peritoneal stripping of right or right and left hemidiaphragm as compared to no subdiaphragmatic peritonectomy (P=1.00 and P=0.58, resp.). In an analysis of 18 quantitative indicators and clinical variables with pulmonary adverse events, only blood replacement greater than six units showed a significant correlation (P=0.0062). Pulmonary adverse events were observed in 10% of patients having CRS and HIPEC. Subphrenic peritonectomy was not a specific risk factor for developing these adverse events.
format Article
id doaj-art-edcf41cda2604af4ad5ad2eb6dca1d1e
institution DOAJ
issn 1687-6121
1687-630X
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-edcf41cda2604af4ad5ad2eb6dca1d1e2025-08-20T03:20:43ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/635314635314Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive PatientsVinicius Preti0David Chang1Paul H. Sugarbaker2Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USAWestat, Rockville, MD 20850, USAWashington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USACytoreductive surgery (CRS) with hyperthermic perioperative chemotherapy (HIPEC) has become a treatment option for selected patients with peritoneal metastases (PMs) from gastrointestinal malignancies. The purpose of this study is to evaluate our most recent data regarding pulmonary complications (respiratory distress, pleural effusion, and pneumonia) and attempt to identify risk factors associated with this management plan. This study includes the most recent 4-year experience with appendiceal and colorectal carcinomatosis patients treated in a uniform manner between January 1, 2006 and December 31, 2009. A prospective morbidity and mortality database was maintained and pulmonary adverse events were analyzed with special attention to subphrenic peritonectomy. There were 147 consecutive patients with a mean age of 49.9 years. Fourteen patients (10%) presented grades I–IV pulmonary complications for a total of 26 events. The peritonectomy of right upper quadrant was performed in 74% and right plus left in 49% of the patients. Statistically, there were no more pulmonary complications among patients submitted to peritoneal stripping of right or right and left hemidiaphragm as compared to no subdiaphragmatic peritonectomy (P=1.00 and P=0.58, resp.). In an analysis of 18 quantitative indicators and clinical variables with pulmonary adverse events, only blood replacement greater than six units showed a significant correlation (P=0.0062). Pulmonary adverse events were observed in 10% of patients having CRS and HIPEC. Subphrenic peritonectomy was not a specific risk factor for developing these adverse events.http://dx.doi.org/10.1155/2012/635314
spellingShingle Vinicius Preti
David Chang
Paul H. Sugarbaker
Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients
Gastroenterology Research and Practice
title Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients
title_full Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients
title_fullStr Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients
title_full_unstemmed Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients
title_short Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients
title_sort pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients
url http://dx.doi.org/10.1155/2012/635314
work_keys_str_mv AT viniciuspreti pulmonarycomplicationsfollowingcytoreductivesurgeryandperioperativechemotherapyin147consecutivepatients
AT davidchang pulmonarycomplicationsfollowingcytoreductivesurgeryandperioperativechemotherapyin147consecutivepatients
AT paulhsugarbaker pulmonarycomplicationsfollowingcytoreductivesurgeryandperioperativechemotherapyin147consecutivepatients